Replimune Group Inc

-1.20 (-6.00%)
4:10:36 PM EDT: $18.80 0.00 (0.00%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Replimune Group Inc Stock, NASDAQ:REPL

500 Unicorn Park Drive, 3rd floor, Woburn, Massachusetts 01801
United States of America
Phone: +1.781.222.9600
Number of Employees: 206


Replimune Group, Inc. is a clinical-stage biotechnology company, which engages in the development of oncolytic immunotherapy product candidates through immulytic platform. Its product candidates include RP1, RP2, and RP3. The firm's Oncolytic immunotherapy is a cancer treatment that exploits the ability of certain viruses to selectively replicate in and directly kill tumors, as well as induce a potent, patient-specific, anti-tumor immune response. The company was founded by Philip Astley-Sparke, Colin A. Love and Robert Coffin in March 2015 and is headquartered in Woburn, MA.